PT - JOURNAL ARTICLE AU - Reed, Susan G. AU - Fan, Sijian AU - Wagner, Carol L. AU - Lawson, Andrew B. TI - Predictors of Developmental Defects of Enamel in the Primary Maxillary Central Incisors using Bayesian Model Selection AID - 10.1101/2022.04.07.22273577 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.07.22273577 4099 - http://medrxiv.org/content/early/2022/04/16/2022.04.07.22273577.short 4100 - http://medrxiv.org/content/early/2022/04/16/2022.04.07.22273577.full AB - Localized non-inheritable developmental defects of tooth enamel (DDE) are classified as enamel hypoplasia (EH), opacity (OP) and post-eruptive breakdown (PEB) using the Enamel Defects Index. To better understand the etiology of DDE, and in particular possibly modifiable variables, we assessed the linkages amongst exposome variables during the specific time duration of the development of the DDE. In general, the human primary central maxillary incisor teeth develop between 13-14 weeks in utero and 3-4 weeks’ postpartum of a full-term delivery, followed by tooth eruption at about 1 year of age. We utilized existing datasets of mother and child dyad data that encompassed 12 weeks’ gestation through birth and early infancy, and child DDE outcomes from digital images of the erupted primary maxillary central incisor teeth. We applied a Bayesian modeling paradigm to assess the important predictors of EH, OP, and PEB. The results of Gibbs variable selection showed a key set of predictors: mother’s pre-pregnancy body mass index (BMI); maternal serum levels of calcium and phosphorus at gestational week 28; child’s gestational age; and both mother’s and child’s functional vitamin D deficiency (FVDD). In this sample of healthy mothers and children, significant predictors for OP included the child having a gestational period > 36 weeks and FVDD at birth, and for PEB included a mother’s pre-pregnancy BMI < 21.5 and higher serum phosphorus level at week 28.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part from: NIH Grants R03 DE029555, R03 DE025082; Data resources support from NIH Grants R01 HD043921, T35 DE007337, T32 DE017551, P20 RR017696, P20 RR01070, P30 GM103331, L1TR000062, UL1 TR001450, The Thrasher Research Fund, AADR Student Research Fellowship and by the South Carolina Clinical & Translational Research (SCTR) Institute with an academic home at the Medical University of South Carolina, NIH/NCRR Grant number UL1 RR029882. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Medical University of South Carolina, Charleston, SC USA gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are available at the completion of the ongoing research and upon reasonable request to the authors.